Cyclin D as a therapeutic target in cancer

Nature Reviews Cancer

Volumn 11, Issue 8, 2011, Pages 558-572

  Musgrove, Elizabeth A ^a,b   Caldon, C Elizabeth ^a   Barraclough, Jane ^a   Stone, Andrew ^a   Sutherland, Robert L ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANDROGEN RECEPTOR; BAY 1000394; BORTEZOMIB; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOTOXIC AGENT; DEXAMETHASONE; ESTROGEN RECEPTOR ALPHA; GEFITINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; ONCOPROTEIN; P 144605; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P21; PROTEIN P27; R 547; RGB 286638; TAMOXIFEN; THYROID HORMONE RECEPTOR BETA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 304709;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ESOPHAGUS CANCER; FATIGUE; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; LEUKEMIA CELL; LIPOSARCOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; MYELOMA CELL; NAUSEA; NONHUMAN; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION REGULATION; VOMITING;

CYCLIN D; HUMANS; NEOPLASMS; ONCOGENES; POLYMORPHISM, GENETIC;

EID: 79960836823     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3090     Document Type: Review

References (190)

1. Sherr, C. J. & Roberts, J. M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18, 2699-2711 (2004) (Pubitemid 39507762)
2. Besson, A., Dowdy, S. F. & Roberts, J. M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 14, 159-169 (2008) (Pubitemid 351189186)
3. Matsushime, H. et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71, 323-334 (1992
4. Meyerson, M. & Harlow, E. Identification of a G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol. 14, 2077-2086 (1994
5. Musgrove, E. A. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24, 13-19 (2006) (Pubitemid 43108773)
6. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011)
7. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nature Rev. Cancer 9, 153-166 (2009)
8. Gil, J. & Peters, G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nature Rev. Mol. Cell. Biol. 7, 667-677 (2006) (Pubitemid 44268212)
9. Chen, H. Z., Tsai, S. Y. & Leone, G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nature Rev. Cancer 9, 785-797 (2009)
10. Lukas, J. et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J. Cell Biol. 125, 625-638 (1994 (Pubitemid 24149844)
11. Matsuura, I. et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430, 226-231 (2004) (Pubitemid 38902433)
12. Shen, R. et al. Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. J. Biol. Chem. 281, 16347-16353 (2006)
13. Zhang, L., Fried, F. B., Guo, H. & Friedman, A. D. Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation. Blood 111, 1193-1200 (2008) (Pubitemid 351213400)
14. Nakajima, K. et al. Coordinated regulation of differentiation and proliferation of embryonic cardiomyocytes by a jumonji (Jarid2)-cyclin D1 pathway. Development 138, 1771-1782 (2011)
15. Lazaro, J. B., Bailey, P. J. & Lassar, A. B. Cyclin D-cdk4 activity modulates the subnuclear localization and interaction of MEF2 with SRC-family coactivators during skeletal muscle differentiation. Genes Dev. 16, 1792-1805 (2002) (Pubitemid 34803895)
16. Kehn, K. et al. Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells. Oncogene 26, 5060-5069 (2007) (Pubitemid 47206950)
17. Adon, A. M. et al. Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells. Mol. Cell. Biol. 30, 694-710 (2010)
18. Wang, C. et al. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc. Natl Acad. Sci. USA 103, 11567-11572 (2006) (Pubitemid 44182492)
19. Zacharek, S. J., Xiong, Y. & Shumway, S. D. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Res. 65, 11354-11360 (2005) (Pubitemid 41821692)
20. Aggarwal, P. et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 18, 329-340 (2010)
21. Ren, J. et al. Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis. J. Biol. Chem. 285, 12695-12705 (2010)
22. Sarcevic, B., Lilischkis, R. & Sutherland, R. L. Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-cyclin-CDK complexes. J. Biol. Chem. 272, 33327-33337 (1997 (Pubitemid 28023683)
23. Baker, G. L., Landis, M. W. & Hinds, P. W. Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle 4, 330-338 (2005) (Pubitemid 41365343)
24. Zhong, Z. et al. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res. 70, 2105-2114 (2010)
25. Neumeister, P. et al. Cyclin D1 governs adhesion and motility of macrophages. Mol. Biol. Cell 14, 2005-2015 (2003) (Pubitemid 36583549)
26. Li, Z. et al. Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol. Cell. Biol. 26, 4240-4256 (2006) (Pubitemid 43788023)
27. Li, Z. et al. Cyclin D1 induction of cellular migration requires p27(KIP1). Cancer Res. 66, 9986-9994 (2006) (Pubitemid 44672051)
28. Chow, Y. H. et al. Role of Cdk4 in lymphocyte function and allergen response. Cell Cycle 9, 4922-4930 (2010)
29. Bienvenu, F. et al. Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature 463, 374-378 (2010)
30. McMahon, C., Suthiphongchai, T., DiRenzo, J. & Ewen, M. E. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc. Natl Acad. Sci. USA 96, 5382-5387 (1999) (Pubitemid 29234626)
31. Reutens, A. T. et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol. Endocrinol. 15, 797-811 (2001) (Pubitemid 32411317)
32. Fu, M. et al. Cyclin D1 inhibits peroxisome proliferator-activated receptor γ-mediated adipogenesis through histone deacetylase recruitment. J. Biol. Chem. 280, 16934-16941 (2005) (Pubitemid 41389153)
33. Coqueret, O. Linking cyclins to transcriptional control. Gene 299, 35-55 (2002) (Pubitemid 35379826)
34. Fu, M., Wang, C., Li, Z., Sakamaki, T. & Pestell, R. G. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145, 5439-5447 (2004) (Pubitemid 39564581)
35. Mullany, L. K. et al. Distinct proliferative and transcriptional effects of the D-type cyclins in vivo. Cell Cycle 7, 2215-2224 (2008) (Pubitemid 352031524)
36. Neuman, E. et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol. 17, 5338-5347 (1997 (Pubitemid 27357632)
37. Zwijsen, R. M. L. et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell 88, 405-415 (1997 (Pubitemid 27131382)
38. Despouy, G. et al. Cyclin D3 is a cofactor of retinoic acid receptors, modulating their activity in the presence of cellular retinoic acid-binding protein II. J. Biol. Chem. 278, 6355-6362 (2003) (Pubitemid 36800894)
39. Sarruf, D. A. et al. Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor γ. Mol. Cell. Biol. 25, 9985-9995 (2005) (Pubitemid 41572745)
40. Knudsen, K. E., Cavenee, W. K. & Arden, K. C. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res. 59, 2297-2301 (1999) (Pubitemid 29242271)
41. Zong, H. et al. Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor. Mol. Cell. Biol. 27, 7125-7142 (2007) (Pubitemid 47549750)
42. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1 phase progression. Genes. Dev. 13, 1501-1512 (1999) (Pubitemid 29297917)
43. Besson, A., Assoian, R. K. & Roberts, J. M. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nature Rev. Cancer 4, 948-955 (2004) (Pubitemid 39626218)
44. Jirawatnotai, S. et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 474, 230-234 (2011)
45. Li, Z. et al. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res. 70, 8802-8811 (2010)
46. Raderschall, E. et al. Formation of higher-order nuclear Rad51 structures is functionally linked to p21 expression and protection from DNA damage-induced apoptosis. J. Cell Sci. 115, 153-164 (2002) (Pubitemid 34105538)
47. Kozar, K. et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118, 477-491 (2004) (Pubitemid 39485667)
48. Malumbres, M. et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118, 493-504 (2004) (Pubitemid 39485668)
49. Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P. & Hinds, P. W. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9, 13-22 (2006) (Pubitemid 43069507)
50. Geng, Y. et al. Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc. Natl Acad. Sci. USA 98, 194-199 (2001) (Pubitemid 32095886)
51. Tsutsui, T. et al. Targeted disruption of CDK4 delays cell cycle entry with enhanced p27Kip1 activity. Mol. Cell. Biol. 19, 7011-7019 (1999) (Pubitemid 29441883)
52. Yasui, M. et al. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin. Cancer Res. 12, 4720-4729 (2006) (Pubitemid 44297826)
53. Nelsen, C. J. et al. Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy. J. Biol. Chem. 280, 768-776 (2005) (Pubitemid 40165045)
54. Pontano, L. L. et al. Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability. Mol. Cell. Biol. 28, 7245-7258 (2008)
55. Shields, B. J., Hauser, C., Bukczynska, P. E., Court, N. W. & Tiganis, T. DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progression. Cancer Cell 14, 166-179 (2008)
56. Aggarwal, P. et al. Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev. 21, 2908-2922 (2007) (Pubitemid 350133439)
57. Yu, Q., Geng, Y. & Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-1021 (2001) (Pubitemid 32612319)
58. Yu, Q. et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9, 23-32 (2006) (Pubitemid 43069508)
59. Yang, C. et al. The role of the cyclin D1-dependent kinases in ErbB2-mediated breast cancer. Am. J. Pathol. 164, 1031-1038 (2004) (Pubitemid 38235484)
60. Hu, M. G. et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 69, 810-818 (2009)
61. Sicinska, E. et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4, 451-461 (2003) (Pubitemid 38050042)
62. Berthet, C. & Kaldis, P. Cell-specific responses to loss of cyclin-dependent kinases. Oncogene 26, 4469-4477 (2007) (Pubitemid 47037044)
63. Cole, A. M. et al. Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res. 70, 8149-8158 (2010).
64. Kim, J. K. & Diehl, J. A. Nuclear cyclin D1: an oncogenic driver in human cancer. J. Cell. Physiol. 220, 292-296 (2009)
65. Gautschi, O., Ratschiller, D., Gugger, M., Betticher, D. C. & Heighway, J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 55, 1-14 (2007) (Pubitemid 46038884)
66. Comstock, C. E., Revelo, M. P., Buncher, C. R. & Knudsen, K. E. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br. J. Cancer 96, 970-979 (2007) (Pubitemid 46452276)
67. Dhar, K. K. et al. Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells. Br. J. Cancer 81, 1174-1181 (1999)
68. Ahmed, K. M., Fan, M., Nantajit, D., Cao, N. & Li, J. J. Cyclin D1 in low-dose radiation-induced adaptive resistance. Oncogene 27, 6738-6748 (2008)
69. Knudsen, K. E., Diehl, J. A., Haiman, C. A. & Knudsen, E. S. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25, 1620-1628 (2006)
70. Kim, C. J. et al. Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells. Mol. Carcinog. 48, 953-964 (2009)
71. Li, Z. et al. Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J. Biol. Chem. 283, 7007-7015 (2008)
72. Zhu, J., Sen, S., Wei, C. & Frazier, M. L. Cyclin D1b represses breast cancer cell growth by antagonizing the action of cyclin D1a on estrogen receptor α-mediated transcription. Int. J. Oncol. 36, 39-48 (2010)
73. Burd, C. J. et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc. Natl Acad. Sci. USA 103, 2190-2195 (2006) (Pubitemid 43271645)
74. Santarius, T., Shipley, J., Brewer, D., Stratton, M. R. & Cooper, C. S. A census of amplified and overexpressed human cancer genes. Nature Rev. Cancer 10, 59-64 (2010)
75. Wang, T. C. et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369, 669-671 (1994 (Pubitemid 24199473)
76. Bertoni, F., Rinaldi, A., Zucca, E. & Cavalli, F. Update on the molecular biology of mantle cell lymphoma. Hematol. Oncol. 24, 22-27 (2006)
77. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008)
78. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010)
79. Matsubayashi, H. et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin. Cancer Res. 9, 1446-1452 (2003) (Pubitemid 36418400)
80. Evron, E. et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 61, 2782-2787 (2001) (Pubitemid 32685869)
81. Padar, A. et al. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin. Cancer Res. 9, 4730-4734 (2003) (Pubitemid 37323275)
82. Wiestner, A. et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 109, 4599-4606 (2007) (Pubitemid 46827749)
83. Benzeno, S. et al. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene 25, 6291-6303 (2006) (Pubitemid 44564745)
84. Moreno-Bueno, G. et al. Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 22, 6115-6118 (2003) (Pubitemid 37175891)
85. Barbash, O. et al. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer. Cancer Cell 14, 68-78 (2008) (Pubitemid 351885497)
86. Russell, A. et al. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 18, 1983-1991 (1999) (Pubitemid 29150085)
87. Pabalan, N. et al. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 17, 2773-2781 (2008)
88. Li, R. et al. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. Hum. Pathol. 39, 1792-1801 (2008)
89. Millar, E. K. et al. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene 28, 1812-1820 (2009)
90. Comstock, C. E. et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin. Cancer Res. 15, 5338-5349 (2009)
91. Abramson, V. G. et al. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Anticancer Res. 30, 1279-1285 (2010)
92. Sanchez, G., Delattre, O., Auboeuf, D. & Dutertre, M. Coupled alteration of transcription and splicing by a single oncogene: boosting the effect on cyclin D1 activity. Cell Cycle 7, 2299-2305 (2008)
93. Zeng, X. et al. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2. Oncogene 29, 5103-5112 (2010)
94. Lee, R. J. et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol. 20, 672-83 (2000) (Pubitemid 30023109)
95. Desai, K. V. et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc. Natl Acad. Sci. USA 99, 6967-6972 (2002) (Pubitemid 34526241)
96. Ahnstrom, M., Nordenskjold, B., Rutqvist, L. E., Skoog, L. & Stal, O. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res. Treat. 91, 145-151 (2005) (Pubitemid 40684926)
97. Reis-Filho, J. S. et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod. Pathol. 19, 999-1009 (2006)
98. Bandi, N. et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 69, 5553-5559 (2009)
99. Bonci, D. et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nature Med. 14, 1271-1277 (2008)
100. Jiang, Q., Feng, M. G. & Mo, Y. Y. Systematic validation of predicted microRNAs for cyclin D1. BMC Cancer 9, 194 (2009)
101. Ewen, M. E. & Lamb, J. The activities of cyclin D1 that drive tumorigenesis. Trends Mol. Med. 10, 158-162 (2004) (Pubitemid 38410973)
102. Arnold, A. & Papanikolaou, A. Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol. 23, 4215-4224 (2005) (Pubitemid 46211327)
103. Rosenwald, A. et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3, 185-197 (2003) (Pubitemid 37443390)
104. Jares, P., Colomer, D. & Campo, E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nature Rev. Cancer 7, 750-762 (2007) (Pubitemid 47463673)
105. Bova, R. J. et al. Cyclin D1 and p16INK14A expression predict reduced survival in carcinoma of the anterior tongue. Clin. Cancer Res. 5, 2810-2819 (1999) (Pubitemid 29493956)
106. Lamb, J. et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114, 323-334 (2003) (Pubitemid 36962931)
107. Ertel, A. et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 9, 4153-4163 (2010)
108. Agarwal, R. et al. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin. Cancer Res. 15, 3654-3662 (2009)
109. Sakamaki, T. et al. Cyclin D1 determines mitochondrial function in vivo. Mol. Cell. Biol. 26, 5449-5469 (2006) (Pubitemid 44036212)
110. Yang, C. et al. Identification of cyclin D1-and estrogen-regulated genes contributing to breast carcinogenesis and progression. Cancer Res. 66, 11649-11658 (2006) (Pubitemid 46094176)
111. Sweeney, K. J., Swarbrick, A., Sutherland, R. L. & Musgrove, E. A. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene 16, 2865-2878 (1998) (Pubitemid 28383271)
112. Thomas, G. R., Nadiminti, H. & Regalado, J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int. J. Exp. Pathol. 86, 347-363 (2005) (Pubitemid 41746374)
113. Roy, P. G. & Thompson, A. M. Cyclin D1 and breast cancer. Breast 15, 718-727 (2006) (Pubitemid 44774238)
114. Taneja, P. et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clin. Med. Insights Oncol. 4, 15-34 (2010)
115. Lukas, J., Bartkova, J., Rodhe, M., Strauss, M. & Bartek, J. Cyclin D1 is dispensible for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol. 15, 2600-2611 (1995
116. Knudsen, E. S. & Knudsen, K. E. Tailoring to RB: tumour suppressor status and therapeutic response. Nature Rev. Cancer 8, 714-724 (2008)
117. Kenny, F. S. et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res. 5, 2069-2076 (1999) (Pubitemid 29399260)
118. Elsheikh, S. et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res. Treat. 109, 325-335 (2008) (Pubitemid 351644857)
119. Biliran, H. Jr. et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin. Cancer Res. 11, 6075-6086 (2005) (Pubitemid 41170340)
120. Kornmann, M. et al. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res. 59, 3505-3511 (1999) (Pubitemid 29334515)
121. Musgrove, E. A. & Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nature Rev. Cancer 9, 631-643 (2009)
122. Kalish, L. H. et al. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 10, 7764-7774 (2004) (Pubitemid 39557542)
123. Smalley, K. S. et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 7, 2876-2883 (2008)
124. Noel, E. E. et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am. J. Pathol. 176, 2607-2615 (2010)
125. Shimura, T. et al. Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3β-mediated cyclin D1 overexpression. Oncogene 29, 4826-4837 (2010)
126. Rudas, M. et al. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin. Cancer Res. 14, 1767-1774 (2008) (Pubitemid 351469462)
127. Stendahl, M. et al. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br. J. Cancer 90, 1942-1948 (2004) (Pubitemid 38746334)
128. Weinstein, I. B. & Joe, A. K. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nature Clin. Pract. Oncol. 3, 448-457 (2006) (Pubitemid 44203817)
129. Krause, D. S. & Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172-187 (2005) (Pubitemid 41058349)
130. Lapenna, S. & Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nature Rev. Drug Discov. 8, 547-566 (2009)
131. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770-1783 (2006) (Pubitemid 46628473)
132. Jeselsohn, R. et al. Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 17, 65-76 (2010)
133. Fry, D. W. et al. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases Cdk4 and Cdk6. J. Biol. Chem. 276, 16617-16623 (2001)
134. Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427-1438 (2004)
135. Marzec, M. et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 108, 1744-1750 (2006) (Pubitemid 44316145)
136. Finn, R. S. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11, R77 (2009)
137. Michaud, K. et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 70, 3228-3238 (2010)
138. Wiedemeyer, W. R. et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc. Natl Acad. Sci. USA 107, 11501-11506 (2010)
139. Konecny, G. E. et al. Expression of p16 and Retinoblastoma determines response to CDK 4/6 inhibition in ovarian cancer. Clin. Cancer Res. 17, 1591-1602 (2011)
140. Tan, A. R. et al. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin. Cancer Res. 10, 5038-5047 (2004) (Pubitemid 39099778)
141. Haddad, R. I. et al. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor. Clin. Cancer Res. 10, 4680-4687 (2004) (Pubitemid 38955518)
142. Berkofsky-Fessler, W. et al. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Mol. Cancer Ther. 8, 2517-2525 (2009)
143. Locatelli, G. et al. Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study. Mol. Cancer Ther. 9, 1265-1273 (2010)
144. Diab, S. et al. A phase I study of R547, a novel, selective inhibitor of cell cycle and transcriptional cyclin dependent kinases (CDKs). ASCO Meeting Abstr. 25, 3528 (2007)
145. Schwartz, G. K. et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br. J. Cancer 104, 1862-1868 (2011)
146. O'Dwyer, P. J. et al. A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991. ASCO Meeting Abstr. 25, 3550 (2007)
147. Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A. & Knudsen, E. S. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 29, 4018-4032 (2010)
148. Wang, L. et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood 110, 2075-2083 (2007) (Pubitemid 47443925)
149. Hanse, E. A. et al. Cdk2 plays a critical role in hepatocyte cell cycle progression and survival in the setting of cyclin D1 expression in vivo. Cell Cycle 8, 2802-2809 (2009)
150. Bagella, L. et al. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene 26, 1829-1839 (2007) (Pubitemid 46474634)
151. Arris, C. E. et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 43, 2797-2804 (2000) (Pubitemid 30599637)
152. Gondeau, C. et al. Design of a novel class of peptide inhibitors of cyclin-dependent kinase/cyclin activation. J. Biol. Chem. 280, 13793-13800 (2005) (Pubitemid 40517276)
153. Canela, N. et al. Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A. J. Biol. Chem. 281, 35942-35953 (2006) (Pubitemid 46041326)
154. Adams, P. D. et al. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 16, 6623-6633 (1996) (Pubitemid 26389720)
155. Ball, K. L., Lain, S., Fahraeus, R., Smythe, C. & Lane, D. P. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr. Biol. 7, 71-80 (1997 (Pubitemid 27058942)
156. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004)
157. Day, P. J. et al. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc. Natl Acad. Sci. USA 106, 4166-4170 (2009)
158. Takaki, T. et al. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc. Natl Acad. Sci. USA 106, 4171-4176 (2009)
159. Schiewer, M. J. et al. Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer. Oncogene 28, 1016-1027 (2009)
160. Wang, M. et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia 23, 1320-1328 (2009)
161. Dragnev, K. H. et al. Bexarotene and erlotinib for aerodigestive tract cancer. J. Clin. Oncol. 23, 8757-8764 (2005) (Pubitemid 46211521)
162. Kim, E. S., Lee, J. J. & Wistuba, II. Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. Cancer Prev. Res. 4, 779-782 (2011)
163. Kim, E. S. et al. The BATTLE trial: personalising therapy for lung cancer. Cancer Discovery 1, 44-53 (2011)
164. Dragnev, K. H. et al. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev. Res. 4, 818-828 (2011)
165. Sabatini, D. M. mTOR and cancer: insights into a complex relationship. Nature Rev. Cancer 6, 729-734 (2006) (Pubitemid 44286004)
166. Alao, J. P. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 6, 24 (2007)
167. Shan, J., Zhao, W. & Gu, W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol. Cell 36, 469-476 (2009)
168. Kelland, L. R. in Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents (eds Smith, P. J. & Yue, E. W.) 371-388 (CRC Press, 2007
169. Menu, E. et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res. 68, 5519-5523 (2008)
170. Baughn, L. B. et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 66, 7661-7667 (2006) (Pubitemid 44289224)
171. Kuo, T. C., Chavarria-Smith, J. E., Huang, D. & Schlissel, M. S. Forced expression of CDK6 confers resistance of pro-B ALL to Gleevec treatment. Mol. Cell. Biol. 31, 2566-2576 (2011)
172. Johnson, S. M. et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J. Clin. Invest. 120, 2528-2536 (2010)
173. Biankin, A. V. & Hudson, T. J. Somatic variation and cancer: therapies lost in the mix. Hum. Genet. 5 Jun 2011 (doi:10.1007/s00439-011-1010-0
174. Puyol, M. et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63-73 (2010)
175. Roberts, P. J., Stinchcombe, T. E., Der, C. J. & Socinski, M. A. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J. Clin. Oncol. 28, 4769-4777 (2010)
176. Zwijsen, R. M., Buckle, R. S., Hijmans, E. M., Loomans, C. J. & Bernards, R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 12, 3488-3498 (1998) (Pubitemid 28553241)
177. Siegert, J. L., Rushton, J. J., Sellers, W. R., Kaelin, W. G. Jr. & Robbins, P. D. Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene 19, 5703-5711 (2000)
178. Hardisson, D. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 260, 502-508 (2003) (Pubitemid 37363578)
179. Moreno-Bueno, G. et al. Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. Int. J. Cancer 110, 194-200 (2004) (Pubitemid 38580390)
180. Wu, W. et al. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. Int. J. Gynecol. Cancer 16, 1668-1672 (2006) (Pubitemid 44060396)
181. Li, W. et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 38, 287-301 (2006) (Pubitemid 44266625)
182. Garcea, G., Neal, C. P., Pattenden, C. J., Steward, W. P. & Berry, D. P. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur. J. Cancer 41, 2213-2236 (2005) (Pubitemid 41415597)
183. Toncheva, D. et al. Tissue microarray analysis of cyclin D1 gene amplification and gain in colorectal carcinomas. Tumour Biol. 25, 157-160 (2004) (Pubitemid 39551741)
184. McKay, J. A. et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int. J. Cancer 88, 77-81 (2000)
185. Bergsagel, P. L. & Kuehl, W. M. Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol. 23, 6333-6338 (2005) (Pubitemid 46218843)
186. Siemeister, G. et al. Pharmacologic profile of the oral novel pan-CDK inhibitor BAY 1000394 in chemosensitive and chemorefractory tumor models. Cancer Res. Abstr. 70, 3883 (2010)
187. DePinto, W. et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol. Cancer Ther. 5, 2644-2658 (2006)
188. Cirstea, D. et al. RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDKDependent and Independent Survival Mechanisms. ASH Annual Meeting Abstr. 112, 2759 (2008)
189. Siemeister, G. et al. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. Biomed. Pharmacother. 60, 269-272 (2006) (Pubitemid 44223936)
190. Scott, E. N. et al. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours. Cancer Chemother. Pharmacol. 64, 425-429 (2009)